NCT06788340View on ClinicalTrials.gov

MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

November 1, 2027

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
Interventions
DRUG

PK-model to decide when to dose Vedolizumab and Ustekinumab

the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.

Trial Locations (6)

2650

Dept. of Gastrointestinal Diseases, Hvidovre

5000

Dept. of Gastrointestinal Diseases, Odense

5800

Dept. of medicine, Nyborg

6700

Dept. of Internal Medicin, Esbjerg

7100

Dept. of Medicine, Vejle

9000

Dept. of Gastrointestinal Diseases, Aalborg

All Listed Sponsors
lead

Odense University Hospital

OTHER